GERON CORP (GERN) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$12.50M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income $158.00K; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$13.89M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$12.45M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$12.50M | (m) | $57.48M | (m) | (m) | -$15.83M* | (m) | (m) | $38.86M | (m) |
| 2026-03-31 | Reported | (m) | $158.00K | (m) | $51.84M | (m) | (m) | -$62.91M | (m) | (m) | $35.42M | (m) |
| 2025-09-30 | Reported | (m) | -$13.89M | (m) | $47.23M | (m) | (m) | -$13.58M* | (m) | (m) | $39.00M | (m) |
| 2025-06-30 | Reported | (m) | -$12.45M | (m) | $49.04M | (m) | (m) | -$27.41M* | (m) | (m) | $38.56M | (m) |
| 2025-03-31 | Reported | (m) | -$16.70M | (m) | $39.60M | (m) | (m) | -$47.98M | (m) | (m) | $40.02M | (m) |
| 2024-09-30 | Reported | (m) | -$28.21M | (m) | $28.27M | (m) | $0.00* | -$58.94M* | (m) | (m) | $35.88M | (m) |
| 2024-06-30 | Reported | (m) | -$69.33M | (m) | $882.00K | (m) | $206.00K* | -$53.48M* | (m) | (m) | $39.42M | (m) |
| 2024-03-31 | Reported | (m) | -$56.13M | (m) | $304.00K | (m) | $615.00K | -$62.25M | (m) | (m) | $27.07M | (m) |
| 2023-09-30 | Reported | (m) | -$47.61M | (m) | $164.00K | (m) | $192.00K* | -$50.84M* | (m) | (m) | $18.35M | (m) |
| 2023-06-30 | Reported | (m) | -$51.95M | (m) | $29.00K | (m) | $202.00K* | -$29.60M* | (m) | (m) | $16.49M | (m) |
| 2023-03-31 | Reported | (m) | -$40.09M | (m) | $21.00K | (m) | $372.00K | -$46.37M | (m) | (m) | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$39.95M | (m) | $297.00K | (m) | $171.00K* | -$29.58M* | (m) | (m) | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$27.98M | (m) | $73.00K | (m) | $70.00K* | -$28.64M* | (m) | (m) | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$28.68M | (m) | $123.00K | (m) | $50.00K | -$33.97M | (m) | (m) | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$25.67M | (m) | $109.00K | (m) | $94.00K* | -$22.84M* | (m) | (m) | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$28.89M | (m) | $107.00K | (m) | $0.00* | -$17.81M* | (m) | (m) | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$28.45M | (m) | $137.00K | (m) | $10.00K | -$32.73M | (m) | (m) | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$20.02M | (m) | $108.00K | (m) | $4.00K* | -$15.45M* | (m) | (m) | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$16.76M | (m) | $43.00K | (m) | $195.00K* | -$12.39M* | (m) | (m) | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$16.87M | (m) | $52.00K | (m) | $191.00K | -$26.19M | (m) | (m) | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$15.97M | (m) | $131.00K | (m) | $257.00K* | -$11.98M* | (m) | (m) | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$15.22M | (m) | $101.00K | (m) | $22.00K* | -$8.74M* | (m) | (m) | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$11.30M | (m) | $57.00K | (m) | $45.00K | -$12.74M | (m) | (m) | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$6.80M | (m) | $165.00K | (m) | (m) | -$6.14M* | (m) | (m) | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$7.24M | (m) | $208.00K | (m) | (m) | -$4.50M* | (m) | (m) | (m) | (m) |
| 2018-03-31 | Reported | (m) | -$7.44M | (m) | $318.00K | (m) | (m) | -$7.37M | (m) | (m) | (m) | (m) |
| 2017-09-30 | Reported | (m) | -$7.24M | (m) | $163.00K | (m) | (m) | -$4.42M* | (m) | (m) | (m) | (m) |
| 2017-06-30 | Reported | (m) | -$6.73M | (m) | $174.00K | (m) | (m) | -$4.44M* | (m) | (m) | (m) | (m) |
| 2017-03-31 | Reported | (m) | -$7.49M | (m) | $537.00K | (m) | (m) | -$7.31M | (m) | (m) | (m) | (m) |
| 2016-09-30 | Reported | (m) | -$3.88M | (m) | (m) | (m) | $0.00* | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | Reported | (m) | -$8.91M | (m) | (m) | (m) | $0.00* | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | Reported | (m) | -$9.08M | (m) | (m) | (m) | $26.00K | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | Reported | (m) | $27.02M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | Reported | (m) | -$9.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | Reported | (m) | -$9.46M | (m) | (m) | (m) | $7.00K | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | Reported | (m) | -$9.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | Reported | (m) | -$8.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | Reported | (m) | -$8.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | Reported | (m) | -$8.73M | (m) | (m) | (m) | $0.00* | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | Reported | (m) | -$8.96M | (m) | (m) | (m) | $22.00K* | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | Reported | (m) | -$11.98M | (m) | (m) | (m) | $34.00K | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | Reported | (m) | -$15.88M | (m) | (m) | (m) | $384.00K* | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | Reported | (m) | -$18.48M | (m) | (m) | (m) | $386.00K* | -$13.76M* | (m) | (m) | (m) | (m) |
| 2012-03-31 | Reported | (m) | -$18.92M | (m) | (m) | (m) | $84.00K | -$16.59M | (m) | (m) | (m) | (m) |
| 2011-09-30 | Reported | (m) | -$19.94M | (m) | (m) | (m) | $135.00K* | -$14.27M* | (m) | (m) | (m) | (m) |
| 2011-06-30 | Reported | (m) | -$21.42M | (m) | (m) | (m) | $136.00K* | -$14.04M* | (m) | (m) | (m) | (m) |
| 2011-03-31 | Reported | (m) | -$24.36M | (m) | (m) | (m) | $124.00K | -$12.71M | (m) | (m) | (m) | (m) |
| 2010-09-30 | Reported | (m) | -$18.20M | (m) | (m) | (m) | $122.00K* | -$8.97M* | (m) | (m) | (m) | (m) |
| 2010-06-30 | Reported | (m) | -$16.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$68.58M | (m) | (m) | (m) | (m) | -$111.04M | (m) | (m) | $159.26M | $75.00K |
| 2024-12-31 | Reported | (m) | -$173.73M | (m) | (m) | (m) | $680.00K | -$218.62M | (m) | (m) | $145.73M | $449.00K |
| 2023-12-31 | Reported | (m) | -$193.94M | (m) | $237.00K | (m) | $830.00K | -$167.74M | (m) | (m) | $69.14M | $22.00K |
| 2022-12-31 | Reported | (m) | -$138.55M | (m) | $596.00K | (m) | $431.00K | -$127.38M | (m) | (m) | $43.63M | (m) |
| 2021-12-31 | Reported | (m) | -$114.00M | (m) | $1.39M | (m) | $207.00K | -$95.56M | (m) | (m) | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$76.91M | (m) | $253.00K | (m) | $401.00K | -$66.65M | (m) | (m) | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$72.50M | (m) | $460.00K | (m) | $413.00K | -$43.83M | (m) | (m) | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$31.07M | (m) | $1.07M | (m) | $16.00K | -$21.01M | (m) | (m) | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$29.25M | (m) | $1.06M | (m) | (m) | -$20.56M | (m) | (m) | (m) | (m) |
| 2016-12-31 | Reported | (m) | -$30.65M | (m) | $6.16M | (m) | $57.00K | -$18.37M | (m) | (m) | (m) | (m) |
| 2015-12-31 | Reported | (m) | -$559.00K | (m) | (m) | (m) | $90.00K | -$24.20M | (m) | (m) | (m) | (m) |
| 2014-12-31 | Reported | (m) | -$36.31M | (m) | (m) | (m) | $131.00K | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | Reported | (m) | -$38.96M | (m) | (m) | (m) | $3.00K | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | Reported | (m) | -$71.76M | (m) | (m) | (m) | $862.00K | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | Reported | (m) | -$96.12M | (m) | (m) | (m) | $612.00K | -$62.39M | (m) | (m) | (m) | (m) |
| 2010-12-31 | Reported | (m) | -$111.17M | (m) | (m) | (m) | $836.00K | -$44.29M | (m) | (m) | (m) | (m) |
| 2009-12-31 | Reported | (m) | -$70.23M | (m) | (m) | (m) | $1.44M | -$43.37M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |